Jamp Pharma Corporation Recalls One Lot (D10776B) of Jamp-Atorvastatin Calcium 


Pharmaceutical Recall Related Images

Coppertone® Recalls Specific Lots of Aerosols Sunscreen Sprays
universal meditech skippack medical lab sars cov 2 antigen rapid test kit
medical recall
jamp atorvastatin calcium 10 mg tablets
Jamp-Atorvastatin Calcium 10 mg tablets
  • Product: Jamp-Atorvastatin Calcium. Some bottles may be labelled as 10 mg tablets (DIN 02504197) but contain 40 mg tablets. 
  • Issue:  Health products – Dosage
                 Health products – Labelling
  • What to do: Check your bottle of Jamp-Atorvastatin Calcium, 10 mg tablets to make sure it contains 10 mg tablets and not 40 mg tablets. If you are unsure, contact your pharmacist to check if your bottle contains the correct tablets. If you see incorrect tablets, stop taking the medication and contact your pharmacy immediately for a replacement product. Seek immediate medical attention if you experience serious adverse effects, which may include muscle pain or muscle weakness.

Affected products

ProductCompanyDINLotExpiry Date
Jamp-Atorvastatin Calcium10 mg tablets Jamp Pharma Corporation02504197D10776B06/2023
Jamp-Atorvastatin Calcium40 mg tabletsJamp Pharma Corporation02504219D10776B06/2023
jamp atorvastatin calcium 40 mg tablets
Jamp-Atorvastatin Calcium 40 mg tablets.

Issue

Jamp Pharma Corporation is recalling one lot (D10776B) of Jamp-Atorvastatin Calcium after one bottle labelled to contain 10 mg tablets of Jamp-Atorvastatin Calcium was found to contain 40 mg tablets of Jamp-Atorvastatin Calcium.

Pharmacists may not recognize the error and accidentally repackage and dispense bottles to patients that are labelled as 10 mg atorvastatin calcium tablets (DIN 02504197), but incorrectly contain 40 mg atorvastatin calcium tablets.

Product from the affected lot was sold to pharmacies between May 2022 and August 2022.

Both the 10 mg and 40 mg atorvastatin calcium tablets are similar-looking white and oval shaped tablets; however, the 10 mg tablets have a "10" marked on one side while the 40 mg tablets have a "40" marked on one side. 

Atorvastatin calcium is a prescription drug in the class of statins used to lower cholesterol and other fats in the blood and for prevention of cardiovascular disease such as heart attacks.

Taking too much atorvastatin calcium or more than the prescribed amount for a long period of time (i.e., taking 40 mg of atorvastatin calcium instead of 10 mg atorvastatin calcium) can increase the risk of serious adverse events, including muscle pain or muscle weakness (i.e., rhabdomyolysis, a rare but serious adverse event associated with statins).

The Department is monitoring the company's recall and will inform the public if any new health risks are identified.

What you should do

  • Check your bottle of Jamp-Atorvastatin Calcium, 10 mg tablets to make sure it contains 10 mg tablets and not 40 mg tablets. 10 mg atorvastatin calcium tablets are white to off-white, oval shaped, film-coated tablets, with "10" marked on one side and "AT" marked on the other. 40 mg atorvastatin calcium tablets are white to off-white, oval shaped, film-coated tablets, with "40" marked on one side and "AT" marked on the other.
  • If you are unsure, contact your pharmacist to check if your bottle of Jamp-Atorvastatin Calcium contains the correct tablets.
  • If you see incorrect tablets, stop taking the medication and contact your pharmacy immediately for a replacement product. Return the affected product to your pharmacy for proper disposal.
  • Seek medical attention immediately if you experience any serious adverse effects from atorvastatin calcium which may include muscle pain or muscle weakness.
  • Contact Jamp Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at serviceclient@jamppharma.com, if you have questions about this recall.
  • Report any health product adverse events or complaints to Health Canada.

Additional information for health care professionals:

  • Health care professionals, such as pharmacists, should check bottles labelled as Jamp-Atorvastatin Calcium, 10 mg tablets before dispensing to ensure they contain the correct tablets.
  • Report any unusual packages to the company, and to Health Canada.

Source: Health Canada via PRNewswire


Related Posts

aurobindo pharma usa acetaminophen aspirin and caffeine tablets label
Aurobindo Pharma USA, Inc. Recalls AuroHealth Healthy Living Over the Counter Migraine Relief Acetaminophen/Caffeine Tablets
Aurobindo Pharma USA, Inc. Recalls AuroHealth Healthy Living Over the Counter Migraine Relief Acetaminophen/Caffeine Tablets
clonazepam orally disintegrating tablets
Endo USA, Inc. Recalls Lot 550147301 of Clonazepam Orally Disintegrating Tablets
Endo USA, Inc. Recalls Lot 550147301 of Clonazepam Orally Disintegrating Tablets
volara system
Baxter Issues Urgent Medical Device Recall for Volar System Single-Patient Use Circuit
Baxter Issues Urgent Medical Device Recall for Volar System Single-Patient Use Circuit
umary acido hialuronica
SoloVital Recalls Umary Acido Hialuronica, Suplemento Alimenticio 850 mg Capsules
SoloVital Recalls Umary Acido Hialuronica, Suplemento Alimenticio 850 mg Capsules

Latest Posts

aldi logo
ALDI Recalls Jalapenos, Green Peppers and Green Beans Due to Potential Listeria Contamination
snowfruit logo
JFE Franchising, Inc. Recalls Variety of Products Because Of Possible Listeria
wiers farm cucumber bags and labels
Wiers Farm, Inc Expands Recall on Whole and Salad Cucumbers Due to Possible Listeria
hover 1 dynamo e scooter
DGL Group Recalls Hover-1 Dynamo E-Scooters Sold Exclusively at Walmart
artic cat mountain 600 snowmobile
Textron Specialized Vehicles Recalls 2024 Arctic Cat Mountain 600 Snowmobiles

Leave a Reply

Your email address will not be published. Required fields are marked *

You Are Leaving Us

This link is being provided as a convenience and for informational purposes only it is not an endorsement or an approval of any of the products, services or opinions of the corporation or organization or individual.

Recallinsider.com bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links.